Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Return on Sales (2022 - 2025)

Axsome Therapeutics' Return on Sales history spans 4 years, with the latest figure at 0.15% for Q4 2025.

  • For Q4 2025, Return on Sales rose 48.0% year-over-year to 0.15%; the TTM value through Dec 2025 reached 0.29%, up 46.0%, while the annual FY2025 figure was 0.29%, 46.0% up from the prior year.
  • Return on Sales for Q4 2025 was 0.15% at Axsome Therapeutics, up from 0.28% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.12% in Q1 2023 and bottomed at 4.7% in Q2 2022.
  • The 4-year median for Return on Sales is 0.77% (2024), against an average of 1.11%.
  • The largest annual shift saw Return on Sales skyrocketed 326bps in 2023 before it plummeted -79bps in 2024.
  • A 4-year view of Return on Sales shows it stood at 2.51% in 2022, then surged by 45bps to 1.38% in 2023, then skyrocketed by 54bps to 0.63% in 2024, then soared by 77bps to 0.15% in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Return on Sales are 0.15% (Q4 2025), 0.28% (Q3 2025), and 0.32% (Q2 2025).